This Notice of Funding Opportunitiy (NOFO) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's Disease-Related Dementias (ADRDs): frontotemporal degeneration (FTD, including Pick’s disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This NOFO covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, 2) screening efforts to identify and characterize potential therapeutic agents, and 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This NOFO supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs.
Deadlines:
RFA-NS-24-010 Expiration Date September 09, 2023
Application budgets are limited to no more than $500,000 in direct costs per year and need to reflect the actual needs of the proposed project.
The total project period for a combined R61/R33 application submitted in response to this NOFO may not exceed five years, with no more than four years for the R61 phase and no more than three years for the R33 phase. Applications proposing less than 4 stages of work are expected to request less time.
